CVS
CVS HealthPrevious close
90.25
Change
−0.08 / −0.09%
P/E (TTM) ?
23.8
Market Cap
$116B
1M
+5.32%
S&P 500 −0.91% over same period
Volume / Avg Volume
8.2M / 6.2M
1.33× average
Latest earnings analysisFY2026 Q2Reported 2026-08-05
CVS Health Q2 FY2026: revenue up 7.3%, guidance raised after EPS beat
CVS Health beat on both earnings and revenue and raised full-year guidance, making this a clean quarter. GAAP diluted EPS of $2.31 and adjusted EPS of $2.58 came in well above the $1.8702 consensus estimate, while revenue of $106.096 billion rose 7.3% on the prior year. The margin story is the one to watch: the medical benefit ratio fell to 87.4% as the Health Care Benefits recovery plan took hold.
Read the full analysis →Revenue$106.10BYoY +7.30%
EPS (non-GAAP)$2.58Beatest. $1.87
Next-quarter revenue guidance$414.00BYoY +290.20%
Next-day move−2.93%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-08-05 | $106B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-05-06 | $100B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-10 | $402B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-29 | $103B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-31 | $98.9B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-01 | $94.6B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 65 of its 5-year rangeMid-range
5-year range 10.1 – 204.9 · Median 18.0
Last 4 quarters: $0 in buybacks + $3.4B in dividends, 2.94% of market cap combined
P/E (TTM)
23.8
P/B
1.5
P/S
0.3
Dividend Yield
3.49%
Earnings Reaction
Over the last 6 reports, the stock moved ±2.3% on average on the first trading day after, rising 3 times
Most recent −2.93%
Volatility & Correlation
1-year beta 0.15 · Correlation with S&P 500 0.06Low beta
Annualized volatility 31% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 106.10 | +7.3% | 44.5% | 2.98 | 2.31 |
| FY2026 Q1 | 100.43 | +6.2% | 44.8% | 2.94 | 2.30 |
| FY2025 Q4 | 105.69 | +8.2% | 44.1% | 2.94 | 2.31 |
| FY2025 Q3 | 102.87 | +7.8% | 44.5% | -3.98 | -3.13 |
| FY2025 Q2 | 98.92 | +8.4% | 45.4% | 1.02 | 0.80 |
| FY2025 Q1 | 94.59 | +7.0% | 46.0% | 1.78 | 1.41 |
| FY2024 Q4 | 97.71 | +4.2% | 43.4% | 1.64 | 1.30 |
| FY2024 Q3 | 95.43 | +6.3% | 44.5% | 0.09 | 0.07 |
| FY2024 Q2 | 91.23 | +2.6% | 45.2% | 1.77 | 1.41 |
| FY2024 Q1 | 88.44 | +3.7% | 45.6% | 1.11 | 0.88 |
| FY2023 Q4 | 93.81 | +11.9% | 38.8% | 2.05 | 1.59 |
| FY2023 Q3 | 89.76 | +10.6% | 39.1% | 2.26 | 1.75 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| CVS | 23.8 | +7.3% | 44.5% | +5.32% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |